Gilead has made the decision to withdraw the accelerated approval of Trodelvy (sacituzumab govitecan) for advanced urothelial cancer in the United States.
Five-fraction SBRT is “a robust and viable alternative” to conventionally or moderately fractionated radiotherapy for prostate cancer, researchers say.
Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.